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PERSPECTIVE
Preventing Alzheimer’s Disease
Dennis J. Selkoe
Despite intensive laboratory and clinical research over three decades, an effective treatment to delay
the onset and progression of Alzheimer’s disease is not at hand. Recent clinical trial failures suggest
that we must treat the disease earlier than in its mild to moderate stages, and major progress in
validating presymptomatic biomarkers now makes secondary prevention trials possible. We will learn
more about the natural history of the disease and any partial therapeutic responses from detailed
analyses of recent trial results. This process will likely position the field for success, but only with much
greater investment in all aspects of Alzheimer research and with careful design of future trials.
Few diagnoses in modern medicine evokedeeper apprehension in patient and familythan Alzheimer’s disease (AD). The impli-
cations of having cardiovascular disease, cancer, or
metabolic disease are ominous, but surveys sug-
gest that people particularly fear developing AD.
This is so because Alzheimer’s robs us of our
most human qualities—reasoning, memory, ab-
straction, language, emotional control—and be-
cause a disease-modifying treatment remains
beyond reach. This enormously common neuro-
degenerative disorder affects more than 5 million
Americans and well over 35 million worldwide,
numbers expected to grow dramatically as the
population ages and competing causes of death
in late life continue to recede (1). The projected
rate of rise is even greater in the developing world
than in the high-income countries (2) (Fig. 1).
As with other slowly progressive diseases, pre-
venting AD depends on understanding early steps
in its pathogenesis. Aworldwide research effort dur-
ing the past quarter century has yielded an increas-
ingly detailed picture of the cytopathological,
biochemical, and genetic underpinnings of the
disease, including in its presymptomatic phase,
and the parallel development of biomarker and
neuroimagingmodalities [reviewed in (3, 4)]. The
classical lesions that Alois Alzheimer called atten-
tion to a century ago—extracellular amyloid plaques
and intraneuronal neurofibrillary tangles—were
shown in the mid-1980s to be composed, respec-
tively, of the 42–amino acid b-amyloid protein
(Ab42) and the microtubule-associated protein
tau. By the mid-1990s, decreased Ab42 levels and
increased tau levels in cerebrospinal fluid (CSF)
were associated with a clinical diagnosis of AD
(5). Soon, lowered CSF Ab42 levels were docu-
mented in older people who appeared to have very
early AD (sometimes referred to as mild cognitive
impairment–amnestic type) or were still cogni-
tively normal (6), with the rise in CSF tau levels
generally following the Ab42 decline (4). In the
realm of neuroimaging, progressive hippocampal
and cortical atrophy were measured with increas-
ing precision before and during the clinical phase
of AD, and this brain shrinkage was found to be
accompanied by decreased cerebral metabolism on
fluorodeoxyglucose positron emission tomography
(FDG-PET). By 2004, the synthesis of a blood
brain barrier penetrant, radiolabeled analog of the
amyloid-binding dye thioflavin T [Pittsburgh com-
pound B (PiB)], enabled researchers to image fi-
brillar amyloid deposits in vivo by PET (7). Taken
together, these quantifiable markers of the evolving
disease process in living human patients, now
widely replicated in multiple studies (8), provide
a critical resource for validating preventative and
therapeutic agents in AD.
Pinpointing a Predisposition to AD
A small fraction (<1%) of all AD cases arises
during middle age because of inherited missense
mutations in one of three genes: APP, PSEN1, or
PSEN2. The APP gene codes for the 695-amino-
acid-long b-amyloid precursor protein (APP),
which has salutary functions during brain devel-
opment and in various biological processes in
adulthood (9). All AD-causing mutations in APP
alter amino acids within or immediately flanking
its small ~42-residue Ab region. The PSEN1 and
PSEN2 genes code for two homologous (and re-
dundant) intramembrane aspartyl proteases, pre-
senilin 1 and presenilin 2 (10, 11). Therefore, all
of these AD-causing mutations directly affect
the biochemical reaction that generates Ab42 and
related peptides throughout life, by altering the
substrate (APP) or the protease that cleaves this
substrate (i.e., presenilin, the catalytic component
of g-secretase). The full penetrance of the muta-
tions for early-onset, autosomal dominant AD and
the fact that they result in a neuropathological,
biochemical, and clinical phenotype largely indis-
tinguishable from typical, late-onset (“sporadic”)
AD provide strong genetic evidence for the amy-
loid or Ab hypothesis, which posits that AD arises
in substantial part from a chronic imbalance be-
tween Ab production and Ab clearance in the
brain. Numerous families carrying APP, PSEN1,
or PSEN2 mutations have been studied collect-
ively to determine the time course of fluid bio-
marker changes, neuroimaging changes, and clinical
changes before the expected onset of AD symp-
toms, which is based on the age of symptom on-
set in a parent with the same mutation.
Initial analyses of a familial AD cohort [the
Dominantly InheritedAlzheimerNetwork (DIAN)]
suggest that Ab42 levels in CSF begin to decline
as early as 25 years before expected symptom
onset (12). This is followed by the appearance of
fibrillar amyloid deposits in the brain (as detected
by PiB-PET), increased levels of tau in CSF, and
progressive brain atrophy roughly 15 years be-
fore expected symptom onset (12). Cerebral hypo-
metabolism and subtly impaired episodic verbal
memory seem to begin some 10 years or so be-
fore expected symptoms (12). If this time course
is generally similar to that of sporadic AD, and
there is evidence from cross-sectional studies that
it may be (4), then humans destined to develop
AD have detectable biochemical and histopath-
ological abnormalities two decades or more be-
fore overt clinical symptoms (Fig. 2).
Two key lessons that emerge from
such studies of presymptomatic AD
are that (i) profound brain alterations
occur well before the dementia can
be diagnosed (13) and (ii) therapeu-
tic interventions directed only at the
mild-to-moderate clinical stage may
be too late to ameliorate symptoms.
The latter conclusion is supported by
recent phase 3 trials of certain Ab-
clearing monoclonal antibodies (e.g.,
bapineuzumab) that apparently failed
to significantly slow cognitive and
functional decline over 18 months,
even though such antibodies are ca-
pable of preventing further rises in
amyloid burden (14, 15) and lower-
ing CSF phospho-tau levels, a key
biomarker of AD-type neuronal de-
generation (16).
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Fig. 1. Projected increases in the numbers of people with de-
mentia in high-income countries and in low- and middle-income
countries. [Figure reproduced, with permission, from (2)]
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Moving Toward Prevention Trials
Although antibodies against Ab (anti-Ab) that
enhance clearance of the peptide and other Ab-
lowering agents, such as inhibitors of the b- and
g-secretase enzymes that generate Ab, may still be
shown to provide benefit in mildly symptomatic
AD, the AD field has moved toward a consensus
that secondary prevention (diagnosing and treating
the disease before overt symptoms) is more likely to
slow the pathogenic process (17–19) (Fig. 2). Such
trials might be designed in the following way. Pre-
symptomatic participants who bear deterministic
mutations in APP, PSEN1, or PSEN2 (i.e., auto-
somal dominant AD) could undergo treatment
with an Ab-lowering or -neutralizing agent begin-
ning 2 to 5 years or more before the expected age
of onset of frank symptoms. In such trials, enrol-
lees would have low CSFAb42 levels as well as
brain amyloid deposits (detected by PET imaging)
that exceed normal thresholds, ensuring that they
can potentially respond to an anti-Ab treatment.
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Fig. 2. Aligning potential disease-modifying agents for AD with the course of
the disease. Red boxes indicate the sequence of steps in the discovery of
compounds or biologics as investigational new drugs (INDs) for AD. Blue
boxes, speculative stages in the long presymptomatic and symptomatic phases
of AD in a hypothetical individual who undergoes Ab buildup for one of
several possible reasons (e.g., a presenilin or APP mutation, ApoE4 inher-
itance, increased b-secretase activity, etc.) and develops very early symptoms
by around age 70. Green boxes, clinical trial categories dependent on the
stage of AD. Red X, trials in moderate AD not recommended. Yellow X, trials in
mild AD recommended with caution. [Figure adapted from (35)]
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Participants who do not yet have elevated CSF lev-
els of tau or phosphorylated tau at trial entry could
be compared with participants who already have
these markers of tangle-associated neurodegenera-
tion. Regarding outcomes, the treatment’s capacity
to delay the aforementioned biomarker changes
[amyloid-PETandFDG-PETabnormalities; cerebral
atrophy by volumetric magnetic resonance imaging
(MRI); rising CSF levels of tau and phosphorylated
tau] could be assessed yearly to ascertain the earliest
point of deflection from the pathogenic trajectory of
placebo-treated mutation carriers. Salutary move-
ments of biomarkers would be expected to be seen
first, but these might be accompanied by less de-
cline on challenging cognitive tests that are sensi-
tive to the cardinal manifestations of very early
clinical AD (e.g., episodic memory loss and word
learning and retrieval deficits) rather than more
global cognitive tests [e.g., Alzheimer’s Disease As-
sessment Scale–cognitive subscale (ADAS-cog),
MiniMental State Examination (MMSE)] that have
less sensitivity to detect early progression. Com-
bined assessment of AD biomarker status and
episodicmemory should indicate whether the agent
in question can slow disease progression over a 3-
to 5-year interval. An academic consortium spon-
sored in part by the U.S. National Institutes of
Health (NIH) and the biotechnology company
Genentech has recently been approved to carry out
such a secondary prevention trial with an anti-Ab
(crenezumab) in ~300 presymptomatic members
of a large Colombian pedigree with the presenilin
1Glu280→Ala280missensemutation and a smaller
number of presymptomatic American participants
from the DIAN cohort who carry other presenilin
mutations (20). Another secondary prevention
trial in autosomal dominant AD has been pro-
posed to the NIH by the Alzheimer’s Association
and a consortium of DIAN sites and certain
pharmaceutical companies (21).
In addition to conducting prevention trials in
presymptomatic participants with rare, dominant-
ly inherited AD, it is important to initiate similar
studies as soon as possible in presymptomatic
participants with common, late-onset AD (so-
called sporadic AD). Here, it may be useful to
divide participants by their apolipoprotein E geno-
types, because the rate of AD pathogenesis and
degree of b-amyloid burden are generally greater
in patients with the E4 allele of this gene com-
pared with those with just E3 or E2 alleles, and
side effect profiles may differ. For example, phase
2 trials of bapineuzumab, a humanized monoclo-
nal antibody to Ab, indicated that ApoE4-positive
participants were significantly more likely to de-
velop anMRI change designatedARIA-E (amyloid-
related imaging abnormality–edema or effusion;
formerly called vasogenic edema) thanwereApoE4-
negative participants, presumably related to the
heavier burden of microvascular amyloid in the
former (22). Although only a small minority of
participants treated with passive Ab immunother-
apy show ARIA-E on MRI, and most of these
experience no overt symptoms, subtle effects of
this process on their mental status are possible
and could partially mitigate any cognitive ben-
efits of lowering and neutralizing Ab. For some
types of experimental anti-Ab therapeutics, for
example, the b- or g-secretase inhibitors now un-
der active development, prospective separation
of trial participants by ApoE4 genotype may not
be necessary, and stratification of the outcomes
by genotype can be done at trial’s end. A sec-
ondary prevention trial of an anti-Ab in sporadic
AD subjects (the A4 trial) is currently in ad-
vanced stages of planning by a consortium led
by the Alzheimer’s Disease Cooperative Study
group funded by NIH (23).
Markers Before Mentation
As we move toward more optimal times for dis-
ease modification (i.e., very early symptomatic
AD and secondary prevention before symptoms),
the importance of obtaining CSF samples by lum-
bar puncture on as many trial participants as pos-
sible cannot be overstated. CSF provides a virtually
ideal indicator of the biochemistry of the fun-
damental pathogenic processes of AD in vivo
and in real time. The fact that multiple lengths of
Ab peptides (especially Ab42, 40, and 38) and
total and phosphorylated tau proteins can be quan-
tified in small samples of CSF allows one to ac-
quire simultaneous information about a putative
pathogenic agent (Ab) and a critical neuronal re-
sponse molecule in AD (tau). Preclinical research
shows that the expression of tau is necessary for
Ab peptides [including soluble oligomers that
may contribute prominently to neuronal dysfunc-
tion (24)] to induce neuritic dystrophy and cyto-
skeletal collapse in cultured neurons (25) and
behavioral deficits in APP transgenic mice (26).
In the future, additional CSF analytes (e.g., other
neuronal proteins, monocyte- andmicroglia-derived
cytokines, certain lipids, metal ions, etc.) could
provide a more sophisticated picture of the AD
biochemical phenotype in vivo and also be used
as biomarkers of progression.
The notion that lumbar puncture is uncom-
fortable and generally unacceptable to patients is
badly out of date. Some investigators in Europe
have been collecting CSF samples from partic-
ipants with symptomatic and presymptomatic
AD for many years, and clinicians in the United
States need to catch up. The Alzheimer Disease
Neuroimaging Imitative (ADNI; sponsored by the
NIH and numerous biopharmaceutical companies)
and some individual AD research centers have
documented how feasible and informative routine
CSF analysis can be [e.g., (27, 28)]. Patients and
their families are usually amenable to lumbar punc-
ture once they are informed of how important it is
for accurate diagnosis and for assessment of trial
outcomes, and the procedure can be quickly and
safely performed in an outpatient setting (29). Ideal-
ly, each academic center or practice participating
in AD trials should designate one or two highly
experienced physicians to perform all the lumbar
punctures, as is done for other minimally invasive
diagnostic procedures such as arthroscopy. Al-
though the advent of PET amyloid imaging is a
great boon to the presymptomatic diagnosis of AD,
a low CSF level of Ab42 is an equally if not more
sensitive biomarker indicating that cerebral Ab
deposition is underway (28), and this information
can be acquired at less expense than a PET scan.
Such considerations underscore the reality that
we cannot validate efficacious disease-modifying
agents in AD without strong reliance on bio-
markers. The AD field often discusses the com-
pelling example of blood lipid profiling in coronary
artery disease (CAD), which led to regulatory
approval of the first statin years before these low-
density lipoprotein (LDL)–cholesterol–lowering
drugs were unequivocally proven to prevent heart
attacks (30). This achievement occurred because
elevated cholesterol levels and abnormal lipo-
protein profiles in blood had been tightly linked
to the risk of progressive CAD by many epide-
miological and mechanistic studies (31). The AD
field is now approaching an analogous benchmark,
with numerous CSF and neuroimaging studies con-
sistently validating early changes in CSF Ab42
and tau levels and cerebral amyloid deposition as
indicative of a high risk of developing disease (8). It
took years of clinical use of statins to be certain that
therapeutically lowering LDL-cholesterol helped
preventmorbidity andmortality in CAD (i.e., prove
the cholesterol hypothesis) (30), and yet statin treat-
ment was approved and rapidly expanded before
that. Because neuropathological, genetic, mecha-
nistic, biomarker, and even therapeutic research all
support an early pathogenic role of Ab42, the AD
field needs to follow suit.
Although sensitive memory tests should al-
ways accompany biomarker assays in secondary
prevention trials, rigorous and statistically signif-
icant outcomes on brain and CSF Ab and tau
should be considered for regulatory approval as
long as an amyloid-lowering agent is deemed
safe. Only with more widespread and prolonged
use of a well-tolerated agent that hits AD bio-
marker endpoints can we ultimately determine
whether the agent is efficacious on quality-of-life
outcomes. Surveys indicate that many patients
and their families are willing to undergo exper-
imental testing of preventatives or early treat-
ments, given the current absence of an approved
disease-modifying therapeutic for this terrible,
fatal disease. Approval of a safe agent that was
designed on the basis of our current best under-
standing of ADmechanism should be considered
on biomarker grounds alone, as has sometimes
occurred in other chronic, life-threatening diseases.
Beyond Ab
Why have agents targeting Ab received so much
therapeutic attention in AD? The principal reason
is the wealth of evidence from many indepen-
dent investigators worldwide supporting an early
21 SEPTEMBER 2012 VOL 337 SCIENCE www.sciencemag.org1490
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role for Ab dyshomeostasis in AD pathogenesis.
Nonetheless, there remain appropriate concerns
about Ab as a cause and as a worthy therapeutic
target in AD. Some of the considerable contro-
versy that has swirled around this topic may rep-
resent misunderstandings of data and goals. I will
describe just two key examples. First, there re-
mains debate about whether Ab accumulation is
a cause or an effect of AD. Almost certainly, the
answer is both. When APP or presenilins are mu-
tant, Ab overproduction appears to be the earliest
identifiable molecular event associated with the
development of AD. But in the vast majority of
cases, an imbalance between Ab production and
clearance, which occurs in 100% of patients as
we defineAD, is caused by other upstream events,
most currently unknown. One very important
known cause is inheritance of one or two e4 al-
leles of the apolipoprotein E gene (32). Such cases
were once part of the broad swath of sporadic AD,
but we now recognizeApoE4 as the single greatest
risk factor for the disease besides age. Compelling
evidence indicates that the ApoE4 protein de-
creases cellular clearance of Ab and enhances the
stability of extracellular Ab aggregates in brain
(33), but evidence for additional, non-Ab–mediated
effects, including on tau, is also accruing (34). Even
though Ab cannot be said to be solely causative
in ApoE4 carriers (who may number at least half
of AD cases), an agent that chronically reduces
Ab production (e.g., a b-secretase inhibitor or a
g-secretase modulator) or enhances its clearance
(e.g., a passively administered Ab antibody or an
active Ab vaccine) should be efficacious. In short,
Ab is both cause and effect in AD.
A second misunderstanding is the notion that
therapies lowering Ab could be dangerous be-
cause they would decrease the peptide’s normal
functions. Even years before symptomatic AD,
brain levels of Ab are very substantially increased,
and no currently contemplated therapeutic would
be expected to reduce them to subphysiological
levels, just as therapeutic statin doses do not cause
serum cholesterol to fall to dangerously low lev-
els. Whether the Ab fragment of APP acquired a
biologically important function during evolution
distinct from those of other proteolytic fragments
of the precursor is under intensive study. For ex-
ample, a recent report found that Ab40 and Ab42
peptides can favorably modify peripheral lymph-
oid and myeloid cell function to mitigate against
experimental autoimmune encephalomyelitis, a
mouse model of multiple sclerosis (35). But low-
ering the excessive brain levels of soluble Ab
peptides in AD to subphysiological levels is not
contemplated and would be difficult to achieve.
These and other specific controversies sur-
rounding the Ab hypothesis have been discussed
(36) and are widely viewed as not precluding fur-
ther human research on Ab-lowering strategies.
At the same time, it is crucial to expend more
preclinical and clinical research effort on non-Ab
strategies—for example, lowering excess levels
of tau proteins or down-regulating inflammatory
cells both centrally and peripherally. Unfortu-
nately, these approaches are well behind ther-
apeutic development in the Ab arena. We must
substantially increase research on these alterna-
tive targets while also accelerating our judicious
testing of Ab-directed agents in presymptomatic
or very early AD. Current research funding for
AD is not nearly sufficient; it still represents a
modest portion of the dollars our field needs to
study AD comprehensively, and it is a very small
fraction (<1%) of the enormous costs our society
bears each year to provide care to AD patients.
Reducing AD Risk Without Drugs
Our understanding of environmental factors that
modulate one’s risk of developing AD lags be-
hind our knowledge of the contributing genetic
factors. Nonetheless, this important topic has been
receiving increasing scrutiny. Lifestyle factors that
may reduce the risk of dementia in general and
AD in particular include physical exercise, cog-
nitive activity and educational attainment, and
social engagement. The protective effect of aero-
bic exercise (37, 38) may derive from enhanced
cardiovascular fitness and cerebrovascular health
but possibly also from modifying the biology of
AD, for example, by lowering Ab accumulation
or decreasing neuritic dystrophy. Lifelong intel-
lectual activity and higher educational levels have
been found to lessen the risk of developingAD or
to ameliorate its course (39, 40). In mouse mod-
els, environmental enrichment, including repeated
exposure to novelty, has been shown to decrease
amyloid burden and attendant neuroanatomical
and behavioral deficits (41, 42). Strong social en-
gagement and lack of isolation in the elderly may
contribute to a lower likelihood of developing de-
mentia, including AD, or a slower progression of
symptoms (43, 44). Our current state of knowledge
suggests that changes in lifestyle are unlikely to be
sufficient to stave off the development of AD, par-
ticularly if these changes are instituted close to the
time of clinical onset. However, it is possible that ex-
posure to beneficial lifestyle factors overmany years
could delay the onset and progression of the dis-
ease. This research areamerits rigorous investigation,
given the ongoing challenges of validating a safe
disease-modifying therapeutic and the high costs
that will be incurred with its chronic administration.
Success from Failure
Attempts to treat complex, chronic diseases such
as AIDS or certain forms of cancer have been
marked by major failures before tangible success
emerged. One hopes that this will be the case in
AD. The appropriately intensive effort to test po-
tential AD therapeutics earlier and in more care-
fully designed trials is likely to lead to rigorous
scientific evidence of disease modification before
long. This evidence may arise principally from
biomarker data, although it will likely be accom-
panied by positive trends on cognitive tests. De-
spite being enormously disappointing to patients,
families, and physicians, the field’s recent clinical
trial failures will provide a great deal of concrete
information about what may work partially, what
does not, and where to go next. As a society, we
must invest muchmore and invest more wisely.We
must broaden our therapeutic vision beyondAb and
also move quickly to trials in very early sympto-
matic as well as presymptomatic participants. As
soon as we see independently replicated evidence
of relevant biomarker changes and some cognitive
benefit, we should begin to consider even earlier
(“primary”) prevention trials for middle-aged par-
ticipants bearing ApoE4 alleles. Our patients and
their families should remind us of Churchill’s ex-
hortation: “…never, never, ever quit!”
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PERSPECTIVE
Changing Human Behavior to
Prevent Disease: The Importance of
Targeting Automatic Processes
Theresa M. Marteau,1* Gareth J. Hollands,1 Paul C. Fletcher2
Much of the global burden of disease is associated with behaviors—overeating, smoking, excessive
alcohol consumption, and physical inactivity—that people recognize as health-harming and yet
continue to engage in, even when undesired consequences emerge. To date, interventions aimed at
changing such behaviors have largely encouraged people to reflect on their behaviors. These
approaches are often ineffectual, which is in keeping with the observation that much human behavior is
automatic, cued by environmental stimuli, resulting in actions that are largely unaccompanied by
conscious reflection. We propose that interventions targeting these automatic bases of behaviors may
be more effective. We discuss specific interventions and suggest ways to determine whether and
how interventions that target automatic processes can enhance global efforts to prevent disease.
At the 65th World Health Assembly heldin Geneva in May 2012, health ministerspledged a 25% cut in premature deaths
from the four most prevalent noncommunicable
diseases—diabetes, cardiovascular disease, lung
disease, and cancer—by 2025. Achieving this
will require sizeable shifts in the population dis-
tribution of consumption of calories, tobacco, and
alcohol, as well as increased levels of physical ac-
tivity and fruit and vegetable consumption. But
howmight such changes in behavior be achieved?
Hitherto, nonregulatory approaches to changing
behaviors across individuals and populations have
focused largely on using information to persuade
people of the risks they face and the potential
benefits of change, through clinics or public health
campaigns, such as those aimed at increasing the
consumption of fruit and vegetables or at reducing
the consumption of alcohol. More recent variants
of this approach include personalizing risk mes-
sages using the results of a wide array of biomarker
tests, including blood glucose levels indicating an
increased risk of diabetes and gene variants indi-
cating an increased risk of heart disease. These ap-
proaches have had either modest or no effects on
health-harming behaviors (1, 2).
We propose that the potential for information-
based interventions is fundamentally limited,
given that it is based on a view of human be-
havior that is at odds with psychological and
neuroscientific evidence that much human behav-
ior is not actually driven by deliberation upon the
consequences of actions, but is automatic, cued
by stimuli in the environment, resulting in actions
unaccompanied by conscious reflection (3).
Flexibility Versus Efficiency: Understanding the
Balance in Human Behavior
Throughout our day, we shift between two broad
categories of behavior (4, 5). On the one hand,
we may act in a reflective manner, directing our-
selves toward particular goals, aware of our mo-
tivations and actions and able to halt or modify
them should the need arise. In other instances, we
act without reflection, responding to our sur-
roundings in complex ways while our thoughts
may be far removed. Each of these types of be-
havior has its advantages and disadvantages. The
former is goal-directed, flexible, and rational in-
sofar as it is motivated by explicit beliefs and
desires. But it is also slow, cumbersome, andmeta-
bolically costly, absorbing our attention and pre-
venting other processing. It is especially inefficient
when it comes to routine situations: Why would
one wish to deliberate over each stage of a fa-
miliar route home? The latter behaviors, in their
automaticity, have the advantage of capitalizing
on the routine and the predictable, freeing us to
devote our cognitive capacity to other matters
while nevertheless engaging in complex and fruit-
ful actions. However, in becoming divorced from
awareness and reflection, these automatic behav-
iors lose flexibility and may become out of touch
with conscious desires, proceeding evenwhen the
consequences are unwanted. Thus, we may find
ourselves taking thewell-travelled route homewhen
the original intention had been to call elsewhere.
Although it is usual to draw a complete distinc-
tion between these two broad categories of behav-
ior, in fact they overlap and interact, with any given
behavior consisting of a complex mixture of the
two. Ideally, theywould, and often do, complement
each other, but they may also come into conflict.
This is particularly so in the case of health-related
behaviors, for which people often have competing
goals (such as a pleasure goal of enjoying a cake
versus a health goal of reducing weight). It is per-
haps most useful to think of them in terms of a
balance, with certain factors promoting the more
reflective and others the more automatic behaviors.
Thus, for example, engaging in a task that absorbs
attention may shift us toward more automatic be-
havior. This is illustrated in an experiment showing
that having to remember a long string of numbers
made people more likely to select chocolate cake
than fruit saladwhen presentedwith a forced choice
in the middle of the experiment (6). Stress too can
shift us from being rational and goal-directed to
more automatic, responding to external stimuli and
persisting in actions that are not ultimately helpful.
The above distinction is very relevant to es-
tablished experimental work on habits, which are
actions that occur in response to stimuli without
necessarily bringing tomind the goal of that action.
Habits are contrasted with goal-directed behavior
and form one class of automatic behavior. They
become established by repetition and routine, their
emergence being marked by measurable changes
in brain circuits (7). Although habits constitute an
important class of automatic behavior, it is impor-
tant to note that not all automatic behavior is
habitual. For example, viewing a beer advertise-
ment on television may result in the viewer going
to the fridge for a beer without awareness of the
1Behaviour and Health Research Unit, Institute of Public Health,
University of Cambridge, Cambridge CB2 0SR, UK. 2Department
of Psychiatry, University of Cambridge, Cambridge CB2 0SR, UK.
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“Ninety-nine hundredths or, 
possibly, nine hundred and ninety-
nine thousandths of our activity is 
purely automatic and habitual, 
from our rising in the morning to 
our lying down each night.”
William James (1899)
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